The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Read More…
Industry, Sector and Symbol
Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
Phone480-245-5960
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.79 million
Profitability
Miscellaneous
Employees138
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Joint (NASDAQ:JYNT) Frequently Asked Questions
What is Joint's stock symbol?
Joint trades on the NASDAQ under the ticker symbol "JYNT."
How were Joint's earnings last quarter?
Joint Corp (NASDAQ:JYNT) issued its quarterly earnings data on Thursday, August, 8th. The company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.01. The firm had revenue of $11.17 million for the quarter, compared to analysts' expectations of $11.08 million. Joint had a net margin of 5.38% and a return on equity of 114.93%. View Joint's Earnings History.
When is Joint's next earnings date?
What guidance has Joint issued on next quarter's earnings?
Joint issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $46.242-48.444 million, compared to the consensus revenue estimate of $46.1 million.
What price target have analysts set for JYNT?
5 equities research analysts have issued 1-year price objectives for Joint's shares. Their forecasts range from $21.00 to $30.00. On average, they expect Joint's share price to reach $24.40 in the next year. This suggests a possible upside of 27.4% from the stock's current price. View Analyst Price Targets for Joint.
What is the consensus analysts' recommendation for Joint?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Joint.
What are Wall Street analysts saying about Joint stock?
Here are some recent quotes from research analysts about Joint stock:
- 1. Maxim Group analysts commented, "Market close, JYNT reported relatively inline 2Q19 revenue results and reiterated 2019 guidance. The company opened 14 franchise clinics in 2Q19 versus our estimate of 17, for a total of 417 franchises. JYNT also opened one greenfield clinic bringing that total up to 51. We are increasing our 2020 revenue estimate as we expect the company to continue to open franchise and greenfield clinics while expanding its national footprint. Also, we are introducing our 2020 quarterly estimates." (8/9/2019)
- 2. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (8/10/2019)
Has Joint been receiving favorable news coverage?
News stories about JYNT stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Joint earned a news impact score of -2.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Joint.
Who are some of Joint's key competitors?
Some companies that are related to Joint include TiVo (TIVO), Digital Turbine (APPS), Liberty Tax (TAXA), Quarterhill (QTRH), Acacia Research (ACTG), Research Frontiers (REFR), Finjan (FNJN), XCel Brands (XELB), Marathon Patent Group (MARA), MGT Capital Investments (MGTI), ARC Group (ARCK), Spherix (SPEX), XpresSpa Group (XSPA), Patriot Scientific (PTSC) and American Restaurant Partners LP Class A Partnership Units (ICTPU).
What other stocks do shareholders of Joint own?
Who are Joint's key executives?
Joint's management team includes the folowing people:
- Mr. Peter D. Holt, CEO, Pres & Director (Age 60)
- Jake Singleton, Chief Financial Officer (Age 37)
- Mr. Jorge Armenteros, VP of Operations
- Dr. James Edwards, Chief Chiropractic & Compliance Officer
- Mr. Craig P. Colmar, Sec. (Age 66)
When did Joint IPO?
(JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager.
Who are Joint's major shareholders?
Joint's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bandera Partners LLC (9.90%), BlackRock Inc. (5.58%), Skylands Capital LLC (4.00%), Vanguard Group Inc. (3.90%), HighTower Advisors LLC (2.15%) and Acadian Asset Management LLC (1.85%). Company insiders that own Joint stock include James H Amos Jr, John P Meloun, Peter D Holt and Ronald V Davella. View Institutional Ownership Trends for Joint.
Which major investors are selling Joint stock?
JYNT stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, HighTower Advisors LLC, Susquehanna International Group LLP, Stonebridge Capital Advisors LLC and Greenwood Capital Associates LLC. View Insider Buying and Selling for Joint.
Which major investors are buying Joint stock?
JYNT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Allianz Asset Management GmbH, Morgan Stanley, Vanguard Group Inc., Bank of New York Mellon Corp, Bandera Partners LLC, Wedge Capital Management L L P NC and Alambic Investment Management L.P.. Company insiders that have bought Joint stock in the last two years include James H Amos Jr and Peter D Holt. View Insider Buying and Selling for Joint.
How do I buy shares of Joint?
Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Joint's stock price today?
One share of JYNT stock can currently be purchased for approximately $19.15.
How big of a company is Joint?
Joint has a market capitalization of $265.04 million and generates $31.79 million in revenue each year. The company earns $250,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. Joint employs 138 workers across the globe.View Additional Information About Joint.
What is Joint's official website?
How can I contact Joint?
Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]
MarketBeat Community Rating for Joint (NASDAQ JYNT)
MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
